<DOC>
	<DOC>NCT02153671</DOC>
	<brief_summary>This study is designed to assess whether a live attenuated Influenza vaccine (LAIV) can induce a long-lasting immune memory by comparing the immunologic response to two doses of the OrniFlu® inactivated vaccine given to subjects previously primed with LAIV and subjects who did not received LAIV.</brief_summary>
	<brief_title>Immunogenicity of H5N1 Vaccine Following H5N2</brief_title>
	<detailed_description>This is a an open-label study to evaluate immunogenic activity of the OrniFlu® inactivated influenza vaccine which will be given to healthy adult volunteers who participated in a double blind placebo-controlled study in protocol LAIV H5N2-01 at the Institute of Influenza in September-October 2012.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Legal male or female adult 18 through 51 years of age at the enrollment visit Literate and willing to provide written informed consent A signed informed consent Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination Capable and willing to complete a memory aid and willing to return for all followup visits For females, willing to take reliable birth control measures through Day 56 Participation in another clinical trial involving any investigational agent within the previous three months or planned enrollment in such a trial during the period of this study Receipt of any nonstudy vaccine within four weeks prior to enrollment or refusal to postpone receipt Participation in any other clinical trials involving any H5matched influenza vaccines except that in Protocol LAIVH5N201 Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever Other acute illness at the time of study enrollment Receipt of immunoglobulin or other blood products within three months prior to study enrollment or planned receipt during study period Chronic administration (defined as more than 14 consecutivelyprescribed days) of immunosuppressants and/or immunemodulating therapy within six months prior to study enrollment History of bronchial asthma Hypersensitivity after previous administration of any (not only influenza) vaccines. Other AE following immunization at least possibly related to previous receipt of any (not only influenza) vaccine Suspected or known hypersensitivity to any of the study vaccine components, including protein of chicken eggs Seasonal (autumnal) hypersensitivity to the natural environment Acute or chronic clinically significant abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. Subjects with physical examination findings or clinical laboratory screening results which would be graded 2 or higher on the AE severity grading scale will be excluded from entry into the study History of leukemia or any other blood diseases or solid organ cancer History of thrombocytopenic purpura or known bleeding disorder History of seizures Known or suspected immunosuppressive or immunodeficient condition of any kind, including HIV infection Known chronic HBV or HCV infection Known tuberculosis infection or evidence of previous tuberculosis exposure History of chronic alcohol abuse and/or illegal drug use Pregnancy or lactation. Systemic connective tissue disorders Adrenal gland diseases Hereditary, degenerative and progredient diseases of the nervous system Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives Allergic, including anaphylactic, reactions to any (not only influenza) vaccines</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>LAIV H5N2</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Russia</keyword>
</DOC>